Guardant Health price target raised to $80 from $70 at UBS

UBS raised the firm’s price target on Guardant Health (GH) to $80 from $70 and keeps a Buy rating on the shares following the investor day. The company upped its 2028 sales targets and advanced its cash flow breakeven 12 months earlier, the analyst tells investors in a research note. UBS increased its sales forecasts to reflect more durable volume growth in Guardant’s oncology business and better selling prices.